Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Menstrual cycle variability in midazolam pharmacokinetics.

E D Kharasch1, D Mautz, T Senn

  • 1Anesthesiology Service, Puget Sound Veterans Affairs Health Care System, Seattle, Washington, USA.

Journal of Clinical Pharmacology
|March 12, 1999
PubMed
Summary

Cytochrome P450 3A4 (CYP3A4) activity, crucial for drug metabolism, does not significantly change during the menstrual cycle. This suggests that hormonal fluctuations do not impact CYP3A4 enzyme function in women.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced Fluorescence of Near-Infrared Anti-CEA Antibodies for Visualizing Colorectal Cancers Using Modified Heptamethine Cyanines.

Molecular imaging and biology·2026
Same author

Supporting therapeutic radiographer research amidst growing pressures: "Why is it so challenging to advance radiographer involvement in research development?"

Radiography (London, England : 1995)·2025
Same author

Radiographer educational requirements for adaptive radiotherapy techniques: A mixed-methods regional scoping study.

Radiography (London, England : 1995)·2025
Same author

Withdrawal notice to: Impact of Provision of Abdominal Aortic Calcification Results on Cardiovascular Risk Reducing Behaviours: A 12-Week RCT [Heart, Lung and Circulation, Volume 33, Supplement 4, August 2024, Page S357].

Heart, lung & circulation·2024
Same author

WITHDRAWN: Impact of Provision of Abdominal Aortic Calcification Results on Cardiovascular Risk Reducing Behaviours: A 12-Week RCT.

Heart, lung & circulation·2024
Same author

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) and nonHDL particles rise during normal pregnancy and differ by BMI.

Journal of clinical lipidology·2022

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Endocrinology

Background:

  • Cytochrome P450 3A4 (CYP3A4) is a key enzyme in drug metabolism, processing about half of all medications.
  • Previous speculation suggested that CYP3A4 activity might fluctuate with the menstrual cycle due to hormonal changes.

Purpose of the Study:

  • To investigate whether hepatic CYP3A4 activity varies across different phases of the normal human menstrual cycle.
  • To determine if menstrual cycle hormonal shifts influence the metabolic capacity of CYP3A4.

Main Methods:

  • A study involving 11 healthy female volunteers with normal menstrual cycles.
  • Midazolam, a probe drug for CYP3A4 activity, was administered intravenously on days 2, 13, and 21 of the menstrual cycle.
  • Plasma midazolam concentrations were measured using gas chromatography-mass spectrometry to calculate midazolam clearance.

Related Experiment Videos

Main Results:

  • No significant differences in midazolam plasma disposition were observed between the menstrual, estradiol peak, and progesterone peak phases.
  • Midazolam clearance, a marker of CYP3A4 activity, remained consistent throughout the evaluated menstrual cycle phases.
  • Mean non-compartmental clearances were 7.36 ± 2.73, 6.34 ± 3.59, and 6.23 ± 2.04 ml/kg/min on days 2, 13, and 21, respectively.

Conclusions:

  • Hepatic CYP3A4 activity does not appear to differ significantly on days 2, 13, and 21 of the menstrual cycle.
  • Current findings do not support the need to consider menstrual cycle variability when dosing or designing clinical trials for CYP3A4 substrates.
  • This study provides evidence against hormonal influences on CYP3A4 activity within the normal menstrual cycle.